Target Price | $3.06 |
Price | $0.93 |
Potential |
229.99%
register free of charge
|
Number of Estimates | 7 |
7 Analysts have issued a price target Assertio Therapeutics, Inc. 2026 .
The average Assertio Therapeutics, Inc. target price is $3.06.
This is
229.99%
register free of charge
$3.15
239.70%
register free of charge
$1.77
90.61%
register free of charge
|
|
A rating was issued by 10 analysts: 9 Analysts recommend Assertio Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Assertio Therapeutics, Inc. stock has an average upside potential 2026 of
229.99%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 124.96 | 113.66 |
17.83% | 9.04% | |
EBITDA Margin | 5.65% | 9.40% |
80.59% | 66.38% | |
Net Margin | -17.27% | -35.40% |
92.09% | 104.99% |
7 Analysts have issued a sales forecast Assertio Therapeutics, Inc. 2025 . The average Assertio Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Assertio Therapeutics, Inc. EBITDA forecast 2025. The average Assertio Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Assertio Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Assertio Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.23 | -0.42 |
95.07% | 82.61% | |
P/E | negative | |
EV/Sales | 0.26 |
7 Analysts have issued a Assertio Therapeutics, Inc. forecast for earnings per share. The average Assertio Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Assertio Therapeutics, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 12 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 16 2024 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 25 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.